Mosaic Is Down 18% From Target-Q2 Earnings Must Prove Brazil Is Fixed

Why the $5 Gap to Target Still Matters

After a 35.8% one-year slide, Mosaic still trades about $5 below the mean analyst target-$22.37 versus $27.11. That leaves room for a recovery, but it also means the stock still needs operational proof, not just optimism. After repeated disappointments, investors may still believe in mean reversion, but they are no longer giving management open-ended patience.

Repeated misses make the quarter harder

Tomorrow's report matters because disappointment is no longer unusual. Mosaic has missed EPS estimates in three of its last four quarters. That history changes how the market reads the release: the headline matters less than whether management can show that the latest weakness is narrowing in a credible way.

For Q2, expectations are modest but still concrete: roughly $0.11 EPS on about $3.0998 billion of revenue. Those are not demanding numbers, but they still assume Brazil is stabilizing and input costs stop worsening. That backdrop matters because Q1 ended with a $258 million net loss, driven by idling at Araxá and Patrocínio and higher sulfur and ammonia costs that pressured phosphate margins.

The real question is not whether Mosaic can barely clear the bar. It is whether investors see the Brazil problem as being resolved, or merely paused.

What Has to Improve for Wall Street to Reprice Mosaic

A small Q2 EPS beat alone is unlikely to send analysts rushing back toward the target. The more important test is whether investors see three things at once: potash still doing its job, Fertilizantes stopping the bleeding, and management protecting cash while Brazil works through the system. Mosaic's public messaging continues to emphasize core assets, so the market will be watching whether the remaining core businesses can offset the drag from Brazil.

Potash still has to carry the balance sheet

The key signal is whether potash continues to support the company. In Q1, the segment generated $177 million of operating earnings and $275 million of adjusted EBITDA. If that strength holds in Q2, investors can forgive more pain elsewhere. If it weakens, Mosaic stops looking like a fixable Brazil story and starts looking like a broader profitability problem.

Phosphate needs visible cost control

For phosphate, the issue is less about an immediate full recovery and more about showing that damage is contained. Last quarter, the segment posted a $(48) million operating loss, and gross margin per tonne fell to about $2 as higher sulfur and ammonia costs compressed profitability. In Q2, investors will want signs that those costs are easing or at least not getting worse. The market needs evidence that the strain is temporary and operational rather than structural.

Cash discipline is still the trust signal

Capex and cash usage matter because sentiment is already fragile. Mosaic already cut 2026 capex to $1.25 billion and deferred less urgent projects. With free cash flow at $(253) million in Q1, investors will be looking for tighter cash management in Q2. Better discipline does not solve Brazil by itself, but it does make the downside case harder to sustain.

The real debate is whether management is earning trust

If Mosaic shows potash still producing strong operating earnings, phosphate stabilizing, and spending held near current levels, investors may decide management is earning back confidence through execution rather than promises. If not, the market is more likely to treat one cleaner quarter as noise rather than proof of a turnaround.

The Earnings Call Will Matter More Than the Headline Number

The call likely matters more than the print because Mosaic is still a Hold consensus stock trading at $22.37 against a $27.11 target, with 77.54% owned by institutional investors. That is a trust setup, not a momentum setup. Professionals already understand the downside; what they are less likely to reward is another vague recovery narrative.

Four questions to watch on the call

• What is the recovery sequence for Brazil? Management needs to explain how the current idling position could turn into a credible restart path, not just a lower-cost standstill.
• Are Fertilizantes losses narrowing in a measurable way? Investors need evidence on costs, idling, and the timing of any improvement.
• Is potash still strong enough to offset weak phosphate? The segment has been the clearest support for the balance sheet, so any slippage would matter.
• Is cash protection staying in focus? The market wants confirmation that lower spending and disciplined cash usage are continuing while the Brazil issue is resolved.

Positioning depends on evidence, not narrative

This is essentially a trust test. Answers with dates, cost evidence, and cash discipline can reduce skepticism and reopen some upside toward target. Vague answers are more likely to keep buyers on the sidelines, especially with a Hold rating in place. For now, the cleaner stance is to watch for operational and cash-generation improvement before getting more constructive.